Founded in 2024 in Zurich, Maven Health helps to support lifestyle changes and combat early signs of metabolic dysregulation. The company developed a Metabolic Insights test which utilizes Nuclear Magnetic Resonance (NMR) technology to analyse saliva samples, assess and track the metabolic profiles of clients through the measurement of 47 metabolites using saliva. The test reveals crucial insights into key areas such as energy balance and cognitive performance, hence providing personalized metabolite insights and personalized nutritional advice. The test can be repeated every 4–6 months, allowing for effective tracking of lifestyle interventions and dietary changes. The accessible and preventative nature of the test makes it an ideal tool for first-line healthcare professionals.
“We have designed our solution specifically for preventive care and to support the implementation of lifestyle changes to tackle the early signs of metabolic dysregulation. In the future, we envision tackling the two large challenges related to metabolic health: diabetes type II and cardiovascular health,” explains Kevin Hof, co-founder and CTO of Maven Health.
In line with its product development strategy, Maven Health is working with various partners to collect further real-world data and deepen its evidence base. This strategy reinforces the previously completed research trial at EPFL and marks the path to scale to the completion of thousands of tests. This supports Maven Health’s vision to enhance data robustness to offer personalized comparisons based on age, sex and ethnicity. To this end, the company has joined a public-private research consortium to perform a longitudinal nutritional intervention study in 2025, measuring saliva metabolite profiles of hundreds of individuals over six months in combination with other tests such as microbiome analyses.
Entrance in the Netherlands sparks European expansion
To bring its recently launched solution to end users, Maven Health operates on a B2B2C model, working closely with healthcare professionals such as nutritionists, general practitioners, pharmacies, and clinics to deliver its tests. At the moment, the company has exclusively served customers in Switzerland. The newly formed partnership with FutureMedics to distribute the tests in the Netherlands marks the beginning of its broader European presence. Further growth is planned throughout Europe, starting with Germany, Italy, and Austria.
The company, with its team of three core members, is funded by a mix of grants, programs, awards, and investors, including EPFL, Fondation pour l’Innovation Technologique (FIT), Innovation Booster, Future of Health grant, Founderful Campus fund, and S2S Ventures.
(RAN)